Phreesia, Inc. (NYSE:PHR) General Counsel and Secretary Allison C. Hoffman recently sold a significant amount of company stock, transactions filed with the Securities and Exchange Commission reveal. Over two days, Hoffman disposed of shares in the healthcare technology firm, totaling over $109,000.
On September 10, 2024, Hoffman sold 2,622 shares at a weighted average price of $23.25, with individual transaction prices ranging from $22.94 to $23.17. This sale amounted to approximately $60,962. The following day, an additional 2,072 shares were sold at an average price of $23.36 per share, totaling around $48,401. The sales were conducted under a pre-arranged trading plan, known as a Rule 10b5-1 plan, which was adopted on December 20, 2023.
These transactions are part of a mandatory sell-to-cover policy that Phreesia has in place to handle tax withholding obligations for its executives when restricted stock units are settled. This policy is designed to automate the process of selling a portion of the vested shares to cover the taxes due, ensuring that executives remain compliant with tax regulations without having to make discretionary decisions about when to sell.
Following these transactions, Hoffman still holds a substantial amount of Phreesia stock, with 121,003 shares remaining in her possession, according to the filing. The sale represents a routine financial move and is not necessarily indicative of the company's future performance or Hoffman's outlook on the company's value.
Phreesia, Inc. specializes in providing patient intake management solutions for healthcare providers, aiming to streamline operations and improve the patient experience. As with any insider transactions, investors often monitor such sales and purchases for insights into executive sentiment, but it is important to consider the broader context in which these sales occur.
In other recent news, Phreesia Inc . has been the subject of several analyst firms' attention due to its strong financial performance. The healthcare software company reported a 19% year-over-year increase in second-quarter revenue, which slightly surpassed expectations. It also reported a positive EBITDA of $7 million, a notable turnaround from a loss of $12 million in the same quarter of the previous year.
Baird, a financial services firm, increased its price target for Phreesia shares to $34.00, citing the company's strong growth outlook. Truist Securities also adjusted its financial outlook for Phreesia, raising its price target to $31.00 due to revised expectations for the company's financial performance in Fiscal Year 2026. Piper Sandler maintained its Overweight rating on Phreesia shares with a consistent price target of $30.00, expressing a positive outlook on the company's financial performance.
Canaccord Genuity maintained a Buy rating for Phreesia with a steady price target of $34.00, highlighting the company's operational efficiency and focus on long-term profitability. Needham reaffirmed a Buy rating and a price target of $29.00 for Phreesia, projecting a potential double in the adjusted EBITDA margin year over year. These recent developments provide investors with a comprehensive view of Phreesia's market performance and growth profile.
InvestingPro Insights
As Phreesia, Inc. (NYSE:PHR) navigates through a period marked by insider transactions, it's crucial to have a comprehensive view of the company's financial health and market performance. InvestingPro data highlights several key metrics that can provide investors with a clearer picture of Phreesia's current standing.
Despite recent insider sales, Phreesia's market capitalization stands at $1.37 billion, indicating a significant presence in the healthcare technology market. However, the company's Price/Earnings (P/E) Ratio is currently negative at -13.31, reflecting the fact that Phreesia was not profitable over the last twelve months. This aligns with one of the InvestingPro Tips, which notes that analysts do not anticipate the company will be profitable this year. The Price/Book ratio, at 5.46, suggests that the stock is trading at a higher multiple of its book value, which could be a point of consideration for value-focused investors.
On a more positive note, Phreesia has experienced a strong revenue growth of 22.1% over the last twelve months as of Q1 2023. This growth may reflect the company's success in expanding its patient intake management solutions. Additionally, the company has enjoyed a robust return over the last three months, with a 16.36% price total return, hinting at a growing investor confidence in the short term.
InvestingPro Tips for Phreesia also include an observation that seven analysts have revised their earnings upwards for the upcoming period, which could signal expectations for improved financial performance. However, it's important to note that the company does not pay a dividend to shareholders, which may influence investment decisions for those seeking regular income.
For investors seeking further insights and additional InvestingPro Tips for Phreesia, there are more tips available at https://www.investing.com/pro/PHR. These tips can provide a deeper understanding of the company's financial nuances and help investors make more informed decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.